DiaMedica Therapeutics Inc. (DMAC) vs Editas Medicine, Inc. (EDIT)
A side-by-side comparison of DiaMedica Therapeutics Inc. and Editas Medicine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DMAC
DiaMedica Therapeutics Inc.
$8.33HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
EDIT
Editas Medicine, Inc.
$2.84HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — DMAC vs EDIT
growth of $100 · dividends reinvested · last 10yDMAC +113.7% (+7.9%/yr)EDIT -81.4% (-15.5%/yr)DMAC compounded faster over this window
Log scale — wide-divergence pair
DMAC EDIT
DMAC vs EDIT: by the numbers
- •DMAC is the larger company ($449M vs $435M market cap).
- •Both run net losses; DMAC's is the smaller (0.00% vs -157.32% net margin).
Metrics side by side
Valuation
| Metric | DMAC | EDIT |
|---|---|---|
| P/S ratio | N/A | 9.26 |
| P/B ratio | 11.71 | 4.13 |
Profitability
| Metric | DMAC | EDIT |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -245.15% |
| Net margin | 0.00% | -157.32% |
| ROE | -97.92% | -70.24% |
| ROIC | -100.87% | -48.61% |
Growth (annualized)
| Metric | DMAC | EDIT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -10.34% |
| Total return CAGR (5Y) | 16.41% | -40.76% |
Frequently asked
- How have DMAC and EDIT total returns compared?
- Over the past 10 years, DMAC delivered 7.89% and EDIT delivered -15.75% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.